Mateon Therapeutics, Inc. (OTCMKTS:MATN)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a note issued to investors on Wednesday. They currently have a $1.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 334.78% from the company’s previous close.

Separately, Maxim Group restated a “hold” rating on shares of Mateon Therapeutics in a report on Tuesday, August 1st.

Mateon Therapeutics (MATN) opened at $0.23 on Wednesday. Mateon Therapeutics has a 12 month low of $0.16 and a 12 month high of $0.89.

Mateon Therapeutics (OTCMKTS:MATN) last released its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.13) EPS for the quarter.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/hc-wainwright-reiterates-buy-rating-for-mateon-therapeutics-inc-matn/1722952.html.

Mateon Therapeutics Company Profile

Mateon Therapeutics, Inc, formerly OXiGENE, Inc, is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT.

Receive News & Ratings for Mateon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.